Skip to main content
. 2017 Mar 29;129(23):3071–3073. doi: 10.1182/blood-2017-01-764209

Figure 1.

Figure 1.

Pre- and posttreatment head CTs with contrast in a patient with primary refractory PCNSL. (Left) The contrast-enhancing lesion before treatment with nivolumab. (Middle) Complete response following 2 months therapy with nivolumab. (Right) Continued complete response 13 months following initiation of therapy.

HHS Vulnerability Disclosure